An estimated 15% (~48 million) of couples have trouble conceiving.1,2 The use of assisted reproductive technology (ART) by infertile couples is increasing by 5-10% per year and the average patient goes through two IVF cycles with the cost ranging from 40-60,000 USD per year.
As women are delaying childbirth to later reproductive years, this postponement leads to decreased fertility in women, driving the need for diagnostic tests to assess ovarian reserve.
Anti-Müllerian hormone (AMH) is produced by small preantral and early antral follicles, and its levels in serum have been shown to be a reliable indicator of ovarian reserve and ovarian function. Women with high AMH levels have a high ovarian reserve. Women that have few remaining follicles and those that are close to menopause have low levels.
Measuring AMH prior to beginning IVF can provide physicians information to manage their patient’s treatment and their expectations for success or complications. The AMH assay with other clinical and laboratory findings, is used as an aid in the assessment of the ovarian reserve. This may support the identification of women with potentially reduced fertility, without the need for invasive testing, and be conveniently tested for regardless of menstrual cycle timing.
The Siemens Healthineers AMH assay available on the Atellica® IM Analyzer and ADVIA Centaur® Immunoassay Systems is a valuable tool for the assessment of ovarian reserve.
- Rapid and precise assessment of ovarian reserve and fertility status
- Simple integration into routine reproductive endocrinology testing workflow on one platform
- Actionable results from an assay that demonstrates optimal analytical and clinical performance